Opportunities and Challenges of Silicon‐based Nanoparticles for Drug Delivery and Imaging

Karaman, Didem Şen; Kaasalainen, Martti; Kettiger, Hélène; Rosenholm, Jessica M.

doi:10.1002/9781119414018.ch9

Cited by 5 publications

(4 citation statements)

References 162 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We ascribe the stability to the chemistry involved, and the high degree of siloxane-rich bonding after the calcination performed at 550 °C. 32,33 The joint extraction and calcination procedure did, however, expand the pores and broadened the PSD somewhat [full-width half maxima (fwhm) in Table 1, PSD in Figure 1] compared to the Pristine MSPs. Also, MSP 2-C had slightly narrower PSD than MSP 1-C, and the controls had slightly different pore sizes (11.0 ± 0.1 nm for MSP 1-C and 11.9 ± 0.1 nm for MSP 2-C).…”

Section: Extraction and Subsequent Calcination Of Msps From Murine An...mentioning

confidence: 99%

Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans

Iqbal

Robert‐Nicoud

Ciurans-Oset

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Mesoporous silica particles (MSPs) can be used as food additives, clinically for therapeutic applications, or as oral delivery vehicles. It has also been discussed to be used for a number of novel applications including treatment for diabetes and obesity. However, a major question for their possible usage has been if these particles persist structurally and retain their effect when passing through the gastrointestinal tract (GIT). A substantial breaking down of the particles could reduce function and be clinically problematic for safety issues. Hence, we investigated the biostability of MSPs of the SBA-15 kind prepared at large scales (100 and 1000 L). The MSPs were orally administered in a murine model and clinically in humans. A joint extraction and calcination method was developed to recover the MSPs from fecal mass, and the MSPs were characterized physically, structurally, morphologically, and functionally before and after GIT passage. Analyses with N2 adsorption, X-ray diffraction, electron microscopy, and as a proxy for general function, adsorption of the enzyme α-amylase, were conducted. The adsorption capacity of α-amylase on extracted MSPs was not reduced as compared to the pristine and control MSPs, and adsorption of up to 17% (w/w) was measured. It was demonstrated that the particles did not break down to any substantial degree and retained their function after passing through the GITs of the murine model and in humans. The fact the particles were not absorbed into the body was ascribed to that they were micron-sized and ingested as agglomerates and too big to pass the intestinal barrier. The results strongly suggest that orally ingested MSPs can be used for a number of clinical applications.

show abstract

Section: Extraction and Subsequent Calcination Of Msps From Murine An...mentioning

confidence: 99%

Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans

Iqbal

Robert‐Nicoud

Ciurans-Oset

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Therefore, it is pertinent to screen via adequate characterization that the structure of the host material (during the preparation method of carrier) is retained in an unaltered form in case water prevails. The degradation of the carrier material could impair the gate-based drug release from MSNPs, besides complicating the drug release in the in vivo conditions [ 211 ]. The second challenge in the MSNPs’ use for drug delivery relates to their biocompatibility and toxicity in course of the drug delivery to cardiovascular disorders.…”

Section: Future Challenges In the Therapeutic Usage Of Mesoporous Sil...mentioning

confidence: 99%

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leading to relapse with consequent invasion and metastasis. Treatment with CDs is indeed well-versed but it is badly curtailed with accompanying side effects and inadequacies of site-specific drug delivery. As a result, drug carriers ensuring stealth delivery and sustained drug release with improved pharmacokinetics and biodistribution are urgently needed. Core–shell mesoporous silica nanoparticles (MSNPs) have recently been a cornerstone in this context, attributed to their high surface area, low density, robust functionalization, high drug loading capacity, size–shape-controlled functioning, and homogeneous shell architecture, enabling stealth drug delivery. Recent interest in using MSNPs as drug delivery vehicles has been due to their functionalization and size–shape-driven versatilities. With such insights, this article focuses on the preparation methods and drug delivery mechanisms of MSNPs, before discussing their emerging utility in BC treatment. The information compiled herein could consolidate the database for using inorganic nanoparticles (NPs) as BC drug delivery vehicles in terms of design, application and resolving post-therapy complications.

show abstract

“…As a result, nano drug-delivery systems (NDDS) are now known as an emerging field of inquiry due to advantages such as their optimal loading, selective delivery, and controlled release. Thus, silicon-based nanomaterials [ 8 , 9 ], polymers [ 10 ], liposomes, and metal NPs [ 11 ] are used to deliver anti-cancer pharmaceuticals to tumor cells. Polymerized nanomaterials represent promising candidates useful in treating cancer strategies due to their versatile adhesion capacity and flawless biological compatibility [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

A Holographic-Type Model in the Description of Polymer–Drug Delivery Processes

Nica,

Volovat,

Boboc

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

A unitary model of drug release dynamics is proposed, assuming that the polymer–drug system can be assimilated into a multifractal mathematical object. Then, we made a description of drug release dynamics that implies, via Scale Relativity Theory, the functionality of continuous and undifferentiable curves (fractal or multifractal curves), possibly leading to holographic-like behaviors. At such a conjuncture, the Schrödinger and Madelung multifractal scenarios become compatible: in the Schrödinger multifractal scenario, various modes of drug release can be “mimicked” (via period doubling, damped oscillations, modulated and “chaotic” regimes), while the Madelung multifractal scenario involves multifractal diffusion laws (Fickian and non-Fickian diffusions). In conclusion, we propose a unitary model for describing release dynamics in polymer–drug systems. In the model proposed, the polymer–drug dynamics can be described by employing the Scale Relativity Theory in the monofractal case or also in the multifractal one.

show abstract

Opportunities and Challenges of Silicon‐based Nanoparticles for Drug Delivery and Imaging

Cited by 5 publications

References 162 publications

Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans

Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

A Holographic-Type Model in the Description of Polymer–Drug Delivery Processes

Contact Info

Product

Resources

About